Screening vs. diagnostic colonoscopy billing: PT, 33, and the conversion trap.
This one decision drives more gastroenterology denials and patient billing complaints than any other single coding call in the specialty. A colonoscopy that starts as a routine screening and finds a polyp doesn't just change CPT codes — it changes which modifier applies, which diagnosis has to lead the claim, and how much the patient owes, and every one of those answers depends on the payer, not the clinical scenario. This guide covers the full decision tree: the G-code trap Medicare sets that commercial payers don't, PT versus 33, Z12.11 sequencing, the statutory cost-sharing phase-down, and Palmetto's A55069 and A55227 articles by name.
Key takeaways
- Medicare's screening colonoscopy isn't billed on the same code family it converts into. A negative Medicare screening exam is G0105 or G0121; the moment something is found and treated, the claim moves to the CPT diagnostic/therapeutic code with modifier PT — not the G-code with a modifier attached. Commercial payers skip this entirely and use 45378 for both the negative screening claim and the base of a conversion.
- PT and 33 are not interchangeable and the wrong one on the wrong payer strips the patient's cost-sharing protection outright, not just risks a denial.
- Medicare coinsurance on a converted screening colonoscopy is on a statutory phase-down, not a flat rule — 15% through 2026, 10% for 2027–2029, $0 starting 2030 — and it only applies when PT is correctly appended.
- An incomplete exam is not a conversion. Palmetto's A55227 Incomplete Colonoscopy/Failed Colonoscopy article governs a scope that stops short for procedural reasons; A55069 Screening Colonoscopy Converted to a Diagnostic and/or Therapeutic Colonoscopy governs a scope that finds and treats something. Confusing the two miscodes the claim and can cost the patient a second round of cost-sharing on the repeat exam.
Two coding paths, one payer-specific fork
The root of the conversion trap is that Medicare and commercial payers don't structure the base screening claim the same way. Medicare uses dedicated HCPCS codes for a screening colonoscopy that finds nothing requiring intervention: G0121 for average-risk patients, G0105 for high-risk patients (personal or family history of colorectal cancer or adenomatous polyps, inflammatory bowel disease, or a genetic syndrome that elevates risk). Commercial, Medicaid, and ACA marketplace plans generally don't use these G-codes at all — they bill the standard diagnostic base code, 45378, with modifier 33 attached to signal the encounter was preventive.
The trap: when a Medicare screening exam converts, the claim does not become G0121 (or G0105) with a modifier bolted on. It becomes the CPT code matching what was actually done — 45380, 45384, 45385, or 45388 — with modifier PT attached. Billing the G-code and the therapeutic CPT code together on the same claim, thinking one covers the screening intent and the other covers the intervention, reads to the payer as two colonoscopies on the same date and denies as duplicate. There is one procedure, one code, and the modifier is what carries the screening history forward into the diagnostic code.
| Outcome | Medicare | Commercial / Medicaid / ACA marketplace |
|---|---|---|
| Screening exam, nothing found | G0121 (average risk) or G0105 (high risk) — no conversion modifier needed, these codes are inherently screening | 45378 with modifier 33 |
| Screening exam converts — polyp/lesion found and treated | Matching therapeutic CPT code (45380/45384/45385/45388) with modifier PT — not the G-code | Matching therapeutic CPT code with modifier 33 |
| Exam ordered as diagnostic from the start (symptoms, surveillance) | Matching CPT code, no PT | Matching CPT code, no 33 |
PT versus 33: matching the modifier to the payer
Both modifiers mean the same clinical thing — a screening colonoscopy converted to diagnostic or therapeutic because something was found and addressed — but they are not interchangeable, and each carries a different practical effect on the patient's bill.
- Waives the Part B deductible entirely on the converted procedure.
- Triggers the statutory reduced-coinsurance phase-down covered below, instead of standard diagnostic coinsurance.
- 33 on a Medicare claim is frequently not recognized as the screening-conversion signal Medicare expects — the claim can default to full diagnostic cost-sharing, deductible included.
- Signals the ACA-mandated preventive-service protection: $0 patient cost-sharing — no deductible, no coinsurance, no copay — on non-grandfathered plans.
- This is a stronger protection than Medicare's phase-down, since there's no residual coinsurance percentage at all.
- PT on a commercial claim is frequently unrecognized entirely, which strips that zero-cost-sharing protection the patient is legally entitled to and bills the visit as standard diagnostic instead.
The most common version of this error isn't a coder picking the wrong modifier at random — it's a charge-master or scrubber rule that defaults to one modifier regardless of payer type, because the clinical scenario documented in the note looks identical either way. The modifier decision has to be built into the system by payer type, not left to a coder remembering which patient is on Medicare.
Z12.11 sequencing: the diagnosis order that decides how the claim prices
Z12.11 (encounter for screening for malignant neoplasm of colon) — validated live against the FY2026 ICD-10-CM code set as billable for HIPAA transactions — has to lead the diagnosis list in the primary position for the claim to price and cost-share as screening in the first place, on both the negative-exam claim and the converted claim. When a polyp is found, the finding gets added as a secondary diagnosis, most commonly K63.5 (polyp of colon), verified billable, but Z12.11 stays primary. Reversing that order — leading with the finding and relegating the screening intent to secondary — is a quiet way a genuinely screening exam gets priced and cost-shared as diagnostic from the start, independent of whatever modifier gets appended afterward. Payers adjudicate primarily off the primary diagnosis position; the modifier confirms the screening intent, it doesn't establish it on its own.
A symptom-only code (abdominal pain, rectal bleeding) or a personal/family-history code in the primary position instead of Z12.11 has the same effect: the exam prices as diagnostic regardless of what was ultimately found, because the primary diagnosis never established screening intent to begin with. If the patient scheduled the exam for routine colorectal cancer screening, Z12.11 belongs in the primary position on the order and the claim, full stop — even if the physician also happens to be evaluating a minor symptom during the same visit.
The code family: 45380, 45384, 45385, 45388
These four codes carry the conversion modifier most often, and each corresponds to a specific technique, not an interchangeable "found something" catch-all.
| Code | Technique | Documentation anchor |
|---|---|---|
45380 | Biopsy, single or multiple | Site, number of specimens, and appearance of the tissue sampled |
45384 | Removal of lesion(s) by hot biopsy forceps or bipolar cautery | Lesion size, location, and technique used to distinguish it from 45385 |
45385 | Removal of lesion(s) by snare technique | Lesion size and location; the most frequently billed of the four in this family |
45388 | Ablation of tumor, polyp, or other lesion (not amenable to removal by biopsy, hot forceps, or snare) | Why the lesion wasn't amenable to a removal technique instead — this justification is what separates 45388 from 45384/45385 on audit |
Multiple lesions removed by different techniques in the same session are billed with the codes for each technique used, following standard multiple-procedure payment reduction rules for additional endoscopic work in the same family — that's a payment-methodology detail, not a bundling denial, so don't treat a lower-than-expected second-line payment as something to appeal without checking the fee schedule first.
The Medicare cost-sharing phase-down, 2023–2029
Before 2022, a Medicare patient whose screening colonoscopy converted to therapeutic paid full diagnostic coinsurance on the procedure — a widely criticized gap where a preventive service turned into an unexpected bill the moment a polyp was actually found. Congress phased that gap out on a fixed statutory schedule rather than closing it all at once.
| Dates of service | Patient coinsurance |
|---|---|
| 2022 and earlier | Standard diagnostic coinsurance (20%) — the gap this schedule was built to close |
| 2023 through 2026 | 15% |
| 2027 through 2029 | 10% |
| 2030 and after | 0% — full first-dollar coverage, matching a negative screening exam |
Two conditions have to both be true for this schedule to apply: the exam has to have started as a Medicare screening colonoscopy (Z12.11 primary, G0105/G0121-eligible), and modifier PT has to be correctly appended to the resulting therapeutic code. Miss either one and the claim reverts to standard diagnostic cost-sharing with no phase-down protection at all — which is a real, statutorily-avoidable increase in what the patient owes, not a rounding difference. The Part B deductible is waived entirely at every point on this schedule, including today; only the coinsurance percentage phases down over time.
⚠️ On the deductible waiver and phase-down dates specifically: this build could not open CMS's primary regulatory guidance or fee schedule transmittal directly to re-confirm the exact percentages and effective years above against the source (CMS's site returned an access error to every fetch attempt made while researching this page) — the schedule is consistently reported across billing-industry and patient-advocacy sources citing the underlying statute, but verify the current-year coinsurance percentage against CMS's own published guidance before quoting it to a patient or building it into a cost-estimate tool.
Anesthesia is billed separately from this schedule
Moderate sedation or monitored anesthesia care for the colonoscopy is billed and adjudicated as its own line, under its own coverage rules, regardless of which modifier or cost-sharing schedule applies to the procedure code. A patient hearing "your screening colonoscopy is fully covered" should not walk away assuming the anesthesia bill is zero too — confirm both pieces separately when counseling a patient on expected cost, especially on Medicare claims still inside the coinsurance phase-down window.
Incomplete exam versus conversion: A55069 and A55227
These are two different clinical events that get coded through two different Palmetto GBA articles, and mixing them up is its own denial pattern separate from the PT/33 decision itself.
- 1Conversion — A55069, "Billing and Coding: Screening Colonoscopy Converted to a Diagnostic and/or Therapeutic Colonoscopy" (Palmetto GBA, effective 10/01/2025). The scope reached its target and something was found and treated. This is the PT/33 scenario covered throughout this guide.
- 2Incomplete or failed exam — A55227, "Billing and Coding: Incomplete Colonoscopy/Failed Colonoscopy" (Palmetto GBA, effective 10/01/2025). The scope did not reach the cecum for a reason unrelated to findings — poor bowel prep, patient intolerance, a technical obstruction, or a perforation risk that stopped the exam early. This is modifier 53 territory, not PT/33, because nothing was found and treated; the exam simply didn't complete.
Both articles were confirmed directly against the CMS Coverage Database at the contractor, article ID, and effective-date level for this page; the full covered-diagnosis lists and documentation specifics inside each article were not independently re-verified here, so pull the current article text for your MAC before finalizing an order-set or scrubber rule against it — contractors outside Palmetto's jurisdiction may publish the same guidance under different article IDs.
The reason this distinction matters beyond correct coding: an incomplete exam coded correctly as screening-with-modifier-53, rather than mistakenly billed as diagnostic, preserves the patient's ability to have the repeat exam — scheduled once bowel prep or the underlying issue is resolved — also billed and cost-shared as screening. Code the incomplete attempt as diagnostic by mistake, and the patient can end up paying diagnostic cost-sharing on an exam that never actually diagnosed anything, then paying it again on the repeat.
Worked claim examples
| Scenario | Coding | Patient cost-share |
|---|---|---|
| Medicare, average risk, screening exam converts to snare polypectomy | Primary Z12.11, secondary K63.5; procedure 45385-PT (not G0121) | No deductible; 15% coinsurance on the procedure for dates of service through 2026 (see phase-down table) |
| ACA marketplace plan, same clinical scenario | Primary Z12.11, secondary K63.5; procedure 45385-33 | $0 — no deductible, no coinsurance, under the ACA preventive-services mandate |
| Medicare, average risk, exam stops at splenic flexure due to poor prep, nothing found | G0121-53 (not diagnostic); documentation states reason for early termination | Standard screening cost-sharing rules apply to the attempted exam; repeat exam remains billable as screening once completed |
Build the PT/33 decision into the charge master as a payer-type rule, not a coder judgment call, and build the G-code-versus-CPT-code decision into it the same way for Medicare specifically. Both errors look identical on the surface — a screening colonoscopy that found a polyp — but one is a modifier problem and the other is a code-family problem, and a scrubber rule that only checks the modifier misses the G-code version entirely.
Do and don't
- Keep Z12.11 in the primary diagnosis position on both the negative and converted claim.
- Switch Medicare's G0105/G0121 to the matching therapeutic CPT code with PT the moment something is found and treated — never bill both.
- Confirm payer type before selecting PT or 33, every time, not just for patients you know are on Medicare.
- Code a scope that stopped short for procedural reasons as incomplete (modifier 53, A55227), not as a diagnostic conversion.
- Don't bill G0105/G0121 alongside a same-session therapeutic colonoscopy code — it's one procedure, one code.
- Don't default to one modifier across all payers because the clinical note looks the same either way.
- Don't quote a patient "fully covered" without separately confirming the anesthesia line.
- Don't code an incomplete exam as diagnostic just because the operative note mentions attempted findings.
Losing revenue — or patient trust — on colonoscopy conversion claims?
We'll audit a sample of your recent screening-to-diagnostic colonoscopy claims, confirm your PT/33 and G-code logic is payer-correct, and show what's recoverable.
Frequently asked questions
If a Medicare screening colonoscopy converts to diagnostic, does the claim still use a G-code?
No. G0105 and G0121 only apply when the screening exam finds nothing requiring intervention. The moment a polyp is found and removed, the claim switches from the G-code to the matching CPT code in the 45380-45398 family with modifier PT attached — not the G-code with a modifier. Billing G0121 alongside a same-session polypectomy code is a common cause of a same-day duplicate-procedure denial, because the payer sees two codes describing the same colonoscopy encounter.
Does the reduced Medicare coinsurance on a converted screening colonoscopy apply to the anesthesia charge too?
No. The statutory cost-sharing phase-down applies to the colonoscopy procedure code itself when modifier PT is correctly appended. Anesthesia or moderate sedation charges are billed and adjudicated separately from the procedure, under their own coverage and cost-sharing rules, regardless of whether the colonoscopy was screening, converted, or diagnostic from the start. Don't tell a patient their entire visit is covered at the reduced rate based on the PT modifier alone.
Our screening colonoscopy stopped short of the cecum due to poor prep — is that a PT conversion?
No, and billing it as one is a common mistake. A conversion means something was found and treated; an incomplete exam means the scope didn't reach its target for a reason unrelated to findings, which is modifier 53 territory under Palmetto's A55227 Incomplete Colonoscopy/Failed Colonoscopy article, not a PT/33 conversion. Keeping the claim coded as screening (G0121-53 for Medicare, or 45378-53 with the screening diagnosis for commercial) rather than diagnostic is also what preserves the patient's ability to have the repeat exam covered as screening instead of paying diagnostic cost-sharing twice for one incomplete workup.
Verify before billing. CPT is a registered trademark of the American Medical Association; codes here are paraphrased, not reproduced from the CPT Professional edition. CPT, HCPCS and ICD-10 codes, coverage policy, and bundling edits change, including annual code-set updates. This page reflects standard industry practice and is provided for general education — it is not a substitute for your own compliance review, your current payer contracts, or the current-year code sets. Confirm requirements against your specific payer mix before submitting claims.